Promising new drugs and therapeutic approaches for treatment of ovarian cancer—targeting the hallmarks of cancer
Abstract Ovarian cancer remains the most lethal gynecological malignancy. Despite the approval of promising targeted therapy such as bevacizumab and PARP inhibitors, 5-year survival has not improved significantly. Thus, there is an urgent need for new therapeutics. New advancements in therapeutic st...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2025-01-01
|
| Edice: | BMC Medicine |
| Témata: | |
| On-line přístup: | https://doi.org/10.1186/s12916-024-03826-w |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|